Identification of features of fear of progression in people with advanced cancer and systemic treatment: an international modified Delphi study
Evie E.M. Kolsteren,Linda Kwakkenbos,Judith B. Prins,Lucy Davis,Marije van der Lee,Hanneke Poort,Petra Servaes,Louise Sharpe,Sophie Lebel,José A.E. Custers,on behalf of the Delphi Study Participants
DOI: https://doi.org/10.1097/or9.0000000000000135
2024-09-20
Journal of Psychosocial Oncology Research and Practice
Abstract:Progress in new treatment options in the past two decades has led to better survival rates in people with several types of advanced cancer. Approval of new standards of care, such as targeted therapy or immunotherapy, improved progression-free and overall survival outcomes significantly in, for example, metastatic lung cancer or metastatic melanoma. 1,2 Subsequently, the prevalence of people living longer with advanced cancer with an uncertain and poor prognosis while receiving systemic treatment has increased substantially. 3 People with advanced cancer receiving systemic treatment refers to patients with any type of metastatic or locally unresectable, solid, advanced, or incurable cancer and a poor and uncertain prognosis, receiving systemic treatment aimed at prolonging life, including chemotherapy, hormone therapy, immune therapy, or targeted therapy. The life expectancy of these patients remains poor and uncertain due to the complexity of prognostics aggravated by the rapid evolution of treatment options. 4–7 As reported in a recent scoping review, living longer with advanced cancer and systemic treatment has a serious psychosocial impact. 6 Fear, uncertainty, loss, hope, and the impact on social life and work were commonly reported themes. A prominent fear for patients is the fear of the cancer progressing, reflected by tumor growth or the cancer spreading to other body parts, inevitably leading to death. Fear of progression (FoP) has been previously reported as transdiagnostic construct, as the fear that the illness or cancer will recur, progress, or spread, in the same organ or in another part of the body, 8–11 and is strongly related to symptoms of depression and anxiety. 12,13 Fear of cancer recurrence (FCR) is defined as 'fear, worry, or concern relating to the possibility that cancer will come back or progress ' 9 and is considered to be one of the most frequent unmet needs among patients with cancer. 10,14 Some authors have argued that FoP and FCR are nearly identical, whereas others have argued that they are distinct 15,16 and that the definition by Lebel and colleagues 9 confounds them. Indeed, in 2015, an inclusive definition of FCR was proposed 9 that encompassed the possibility of cancer progressing along with recurring, because of its appeal and applicability to all patients with cancer. Research to date on FCR has been mostly focused on early-stage cancer survivors as opposed to patients most often defined as those still in active treatment. However, in the past decades, with the emergence of a new population of patients with cancer living longer with advanced cancer receiving systemic treatment, refining and disentangling FCR and FoP appear to be helpful in advancing research and care for these patients. 17 The experience of this new group of patients appears to be somewhat different from that of other patients with cancer, and they specifically report fearing that their treatment might stop being effective resulting in progression of cancer, stress, and fear regarding frequent scans (eg, every three months), referred to as scanxiety, 18,19 and an overall pervasive sense of uncertainty. 5,6,12,15 Since it is expected that a growing number of people lives longer with advanced cancer and systemic treatment, a considerable amount of people may experience (severe) FoP and could be in need of psychosocial support to cope with this. 6,20 Therefore, it is important and timely to identify features of FoP for this specific patient group and to explore how FoP levels can be assessed, to improve psychosocial outcomes. A significant first step would be to find consensus on the features of FoP in advanced cancer. 21,22 Hence, the objective of this study was to identify features of FoP in people with advanced cancer and systemic treatment with an international modified Delphi study. 23